Publications by authors named "Allan Nichols"
The feasibility and safety of same-day discharge after transvenous implantable cardioverter-defibrillator implantation is well-established. However, subcutaneous ICDs (S-ICDs) are now increasingly being implanted, and the feasibility, safety, and potential cost savings associated with same-day discharge after S-ICD placement has not been widely investigated. In a small cohort of patients (n = 24) who underwent S-ICD implantation at our institution, 54% were successfully discharged on the same day as their implant procedure.
View Article and Find Full Text PDFBackground: Radio-Frequency ablation (RFA) to achieve pulmonary vein isolation (PVI) remains mainstay therapy for symptomatic paroxysmal atrial fibrillation (PAF). The clinical consequences of large saline infusions during AF ablation have not been systematically studied. We utilized the differential flow-rates of the two commercially available ablation catheters (AC): 'ThermoCool' (TCAC) and 'Surround Flow' (SFAC) from Biosense-Webster to evaluate the clinical impact of the saline infused in the immediate post-ablation period.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed the long-term incidence of atrial fibrillation (AF) in patients who suffered a cryptogenic stroke (CS) and received an insertable cardiac monitor (ICM) for detection.
- Over a two-year follow-up, the AF detection rate was found to be 21.5%, with episodes detected in about 238 out of 1247 patients.
- Continuous monitoring with ICMs proved significantly more effective than traditional intermittent monitoring methods for detecting AF, highlighting the importance of ICMs in managing CS patients.
Article Synopsis
- The study investigates the occurrence of atrial fibrillation (AF) in patients who had a cryptogenic stroke and were monitored with an insertable cardiac monitor (ICM).
- Analyzed data from 1,247 patients showed AF detection rates of 4.6% at 30 days and 12.2% at 182 days, indicating a significant increase compared to the previous CRYSTAL AF trial.
- Findings suggest that longer monitoring than the current 30-day guideline may be beneficial for better identifying AF in cryptogenic stroke patients.